Last reviewed · How we verify
CM-24 and Nivolumab - Dose Escalation
At a glance
| Generic name | CM-24 and Nivolumab - Dose Escalation |
|---|---|
| Sponsor | Famewave Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CM-24 and Nivolumab - Dose Escalation CI brief — competitive landscape report
- CM-24 and Nivolumab - Dose Escalation updates RSS · CI watch RSS
- Famewave Ltd. portfolio CI